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Clostridioides difficile infection
Jillian R.-M. Brown1,2†, Burkhardt Flemer1,2†, Susan A. Joyce1,3†, Akbar Zulquernain1,4, Donal Sheehan1,4,
Fergus Shanahan1,4 and Paul W. O’Toole1,2*
Abstract
Background: Alteration of the gut microbiota by repeated antibiotic treatment increases susceptibility to
Clostridioides difficile infection. Faecal microbiota transplantation from donors with a normal microbiota effectively
treats C. difficile infection.
Methods: The study involved 10 patients with recurrent C. difficile infection, nine of whom received transplants
from individual donors and one who received a donor unit from a stool bank (OpenBiome).
Results: All individuals demonstrated enduring post-transplant resolution of C. difficile- associated diarrhoea. Faecal
microbiota diversity of recipients significantly increased, and the composition of the microbiota resembled that of
the donor. Patients with C. difficile infection exhibited significantly lower faecal levels of secondary/ bile acids and
higher levels of primary bile acids. Levels of secondary bile acids were restored in all transplant recipients, but to a
lower degree with the OpenBiome transplant. The abundance increased of bacterial genera known from previous
studies to confer resistance to growth and germination of C. difficile. These were significantly negatively associated
with primary bile acid levels and positively related with secondary bile acid levels. Although reduced levels of the
short chain fatty acids, butyrate, propionate and acetate, have been previously reported, here we report elevations
in SCFA, pyruvic and lactic fatty acids, saturated, ω-6, monounsaturated, ω-3 and ω-6 polyunsaturated fatty acids
(PUFA) in C. difficile infection. This potentially indicates one or a combination of increased dietary FA intake, microbial
modification of FAs or epithelial cell damage and inflammatory cell recruitment. No reversion to donor FA profile
occurred post-FMT but ω-3 to ω-6 PUFA ratios were altered in the direction of the donor. Archaeal metabolism genes
were found in some samples post FMT.
Conclusion: A consistent metabolic signature was identified in the post-transplant microbiota, with reduced primary
bile acids and substantial restoration of secondary bile acid production capacity. Total FA levels were unchanged but
the ratio of inflammatory to non-inflammatory FAs decreased.
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Background
Clostridioides difficile infection is an important hospital
acquired infection [1] with 440 cases reported for the last
quarter of 2017 in Ireland [2]. C. difficile is a Gram-positive
anaerobic bacterium which produce spores that are very
resistant to chemicals, heat and radiation but which may
germinate in the presence of bile salts and glycine into
metabolically active toxin-producing cells [3, 4]. C. difficile
is present in up to 3% of healthy adults, 20% of individuals
on antimicrobial therapy and up to 90% of healthy asymp-
tomatic new-born infants. C. difficile colonization is in-
versely correlated with immunoglobulin A levels in infants
[5] and IgG in adults [6]. Antibiotic treatment affects the
gut microbiota resulting in microbial and metabolic signa-
ture alterations which favour C. difficile overgrowth [7, 8].
Growth of C. difficile is normally suppressed by other an-
aerobic bacteria, but C. difficile colonisation rates increase
with age and reduced stability of the gut microbiome [9].
Decreasing Bacteroidetes abundance may promote C.
difficile colonization because it is associated with higher
abundance of Ruminococcus gnavus and Clostridium
nexile, both of which produce a trypsin-dependant anti-
microbial peptide affecting other clostridial species but
not C. difficile [10]. C. difficile colonization resistance is
maintained by a number of key Firmicutes species
including short chain fatty acid (SCFA) (butyrate) pro-
ducers as well as other species from Clostridium clus-
ters IV and XIVa [11]. The microbiome is responsible
for modifying diverse bile acids in the small intestine
and colon. Members of Clostridium cluster XIVa
metabolize free bile acids (Cholic acid (CA) and Cheno-
deoxycholic acid (CDCA)) to produce signal-altering,
hydrophobic bile acids (Deoxycholic acid and Lithocholic
acid respectively). Upstream conversions by bacterial bile
salt hydrolase enzymes from a wide variety of taxa are the
gateway to further modifications. One important factor
affecting the growth of C. difficile is the generation of
secondary bile acids (deoxycholic acid from CA and
lithocholic acid from CDCA) by 7-alpha-dehydroxylation
[12, 13]. In healthy individuals C. difficile appears to be
suppressed by secondary bile acid levels in the colon.
Interestingly, highly virulent C. difficile strains are signifi-
cantly more tolerant of LCA [14].
The potential to counteract C. difficile overgrowth by
replenishing microbial diversity in the gut is well estab-
lished. Nearly 30 years ago, rectal instillation of a mixture
of 10 different bacterial species successfully treated relaps-
ing C. difficile diarrhoea in 5 patients [15]. Re-colonization
and the reintroduction of microbial diversity also have the
effect of altering downstream metabolite production.
However, while SCFAs in the gut are altered in the murine
C. difficile infection model, [4, 16] the administration of
SCFA alone is insufficient to alleviate disease symptoms
[16]. Nevertheless, restoration of the bile acid and salt
balance appears to be an effective means by which the gut
microbiota suppresses C. difficile colonization and out-
growth [17].
Methanogens belong to the domain Archaea, and
although variably present in the intestine, their role in
human disease is not well established. The predominant
methanogen in the human gut is Methanobrevibacter
smithii, [18–20].Methanosphaera stadtmanae is also found
in humans, but less frequently [21]. Some methanogens
harbour genes that were possibly acquired by lateral gene
transfer from gut Firmicutes, allowing their growth in the
presence of bile salts [22]. These archaea are capable of
symbiotic interactions with other bacteria that enhance
SCFA production [23, 24].
The aim of this study was to investigate microbial
community dynamics and metabolic changes associated
with successful FMT. We used 16S rRNA gene profiling
and shotgun metagenome sequencing to compare the
microbiota of healthy donors and patients with C. difficile
infection, before and after FMT. We determined faecal
bile and fatty acid profiles to investigate associations with
microbiota changes observed.
Methods
Patients
All patients were recruited by direct referral from out-
patient gastroenterology clinics or the in-patient services
at Cork University Hospital, Ireland. Patients had a his-
tory of diarrhoea and toxin-positive C. difficile infection
following antibiotic therapy (Table 1). Inclusion criteria
for FMT included recurrent C. difficile diarrhoea following
primary anti-C. difficile therapy. The study was approved
by the Clinical Research Ethics Committee of the Cork
Teaching Hospitals. Informed written consent was ob-
tained from all patients. A complete antibiotic history was
recorded. A faecal sample was collected and tested
for C. difficile, enteric infections and parasites. Diagnostic
C. difficile assay was by real time PCR (polymerase chain
reaction) for tcdB (C. difficile toxin B) in faeces (Enteric-
Bio®, Serosep Ltd., Limerick, Ireland). Serological screening
prior to FMT included Human Immunodeficiency virus,
Hepatitis B & C and syphilis.
Donor identification and screening
Patients and relatives were asked to identify potential
donors from among their family and friends. The do-
nor’s past and current medical history, including any
abdominal symptoms, antibiotic use, travel history and
assessment for transmissible disease, were recorded and
reviewed. Informed written, donor consent was obtained.
Donors underwent laboratory serologic testing for Hepatitis
B, C, cytomegalovirus, Epstein Barr virus, Human Immuno-
deficiency Virus and Treponema pallidum. Donor stool was
screened for C. difficile, common enteropathogens, ova,
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cysts and parasites as described [25]. In the single case
that a suitable personal donor was not available, a banked
stool donor unit from Open-Biome (www.openbiome.org)
was used.
Anaerobic preparation of inoculum for faecal microbiota
Transplantation (FMT)
Faecal samples were collected from the donor and proc-
essed in a dedicated anaerobic cabinet less than 1 h post
voiding. Published protocols [26, 27] were used for the
preparation of the faecal suspension and infusion, with
the modification that all processes were carried out an-
aerobically under N2 gas flow. Briefly, the sample was
weighed (> 50 g) and homogenized in 250 ml physio-
logical saline (0.9%). The faecal slurry was then sieved
through a sterile 0.25 mm sieve lined with two unfolded
gauze sheets to remove larger particles and to prevent
syringe blockage. The faecal suspension container was
topped up with saline leaving no headspace and immedi-
ately transferred anaerobically (or on ice if using Open
Biome sample) to the endoscopy suite, where it was
administered to the patient within 1 h after preparation.
FMT procedure
The night before the procedure, the patients took
bowel preparation containing polyethylene glycol
(Movicol®, Norgine Ltd) to remove residual luminal
antibiotics and faecal material. The patients underwent
an esophago-gastro-duodenoscopy and full colonos-
copy under conscious sedation. Faecal suspension
(120 ml) was infused in the distal duodenum via a
gastroscope. The remaining 180 ml was administered
commencing from the distal ileum and right colon dur-
ing withdrawal of the colonoscope. Patients were clinically
followed and stool was obtained for C. difficile toxin 2
weeks and 8 weeks post procedure. Treatment was de-
fined as successful if there was symptomatic clinical
improvement and when C. difficile testing was negative.
Sample collection
Faecal samples were collected from patients prior to
FMT and between 12 and 180 days following the proced-
ure. An aliquot of donor stool was collected on the day of
the procedure. DNA (deoxyribonucleic acid) from stool
samples was extracted immediately. Stool from both
donor and recipient was stored at − 80 °C for bile and fatty
acid analysis.
DNA extraction, library preparation and 16S amplicon
sequencing
Genomic DNA was extracted from faecal samples (0.25 g)
using the Repeat Bead Beating (RBB) method of Yu and
Morrison [28] with the following modifications. Sterile
zirconia beads (0.5 g) collections of (one 3.0 mm bead,
0.1 g of 0.5 mm beads, and 0.3 g of 0.1 mm beads) were
used. Faecal samples were homogenised via bead beating
for 90 s (Mini-Beadbeater™, BioSpec Products, Bartlesville,
OK, USA), with the samples cooled on ice for 60 s before
another 90 s bead beating. Pooled supernatants were incu-
bated with 350 ml of 7.5 M ammonium acetate (Sigma).
The extraction then proceeded as per the RBB extraction
protocol. Genomic DNA was visualised on 1% agarose gel
and quantified using the Nanodrop 1000 (Thermo
Scientific, Ireland). Extracted genomic DNA was stored at
− 20 °C until amplification. Bacterial primers used for PCR
amplification targeting the V3-V4 hypervariable region of
the 16S rRNA gene are listed in Additional file 1: Table S1
[29]. Illumina overhang adapter sequences were appended
to the 16S rRNA gene specific primer sequence. The PCR
master mix comprised 0.2 μM forward and reverse 16S
amplicon primers (EUROFINS, Ebersberg, Germany),
15 μl of 1X Phusion Taq High-Fidelity Mix (Thermo
Scientific, Ireland), 10 ng DNA and nuclease free water to
30 μl. The following PCR program was used: 1. 98 °C
for 30s, 2. 98 °C for 10s, 3. 55 °C for 15 s, 4. 72 °C for 20s,
5. 72 °C for 5 min. Steps 2-4 were repeated for 25 cycles.
Amplicons were visually checked on 2% agarose gels and
Table 1 Clinical characteristics of the patient population in this study
Patient Age Sex Antibiotics Pre C. difficile infection Antibiotics used to treat C. difficile infection Resolution of C. difficile infection
1 35 F Co-amoxiclavMetronidazole Metronidazole, Vancomycin, Fidaxomicin No
3 35 F As above As above Yes
2 24 F Erythromycin Azithromycin Vancomycin, Fidaxomicin Yes
4 54 F Co-amoxiclav Metronidazole, Vancomycin, Fidaxomicin Yes
5 69 F Tazobactam, Piperacillin Co-amoxiclav Metronidazole Vancomycin Fidaxomicin Yes
6 65 F Flucoloxacillin Calvepen Benzylpenicillin
Co-amoxiclav
Metronidazole, Vancomycin Yes
7 90 F Cefuroxime Cephalexin Metronidazole Vancomycin Fidaxomicin Yes
8 58 F Tazobactam Piperacillin Vancomycin, Meropenem Metronidazole Vancomycin Fidaxomicin Yes
10 22 M None Vancomycin Yes
11 68 M Tazobactam Piperacillin Metronidazole Vancomycin Fidaxomicin Yes
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purified by magnetic purification using SPRI select beads
(Beckman Coulter). The amplicon was then bar-coded
using a limited cycle PCR and Nextera XT dual index bar-
codes (Illumina, Netherlands) (Additional file 1: Table S1).
The PCR master mix comprised 5 μl forward and reverse
Nextera primer respectively (Illumina, Netherlands), 25 μl
of 1X Phusion Taq High-Fidelity Mix (Thermo Scientific,
Ireland), 5 μl PCR amplicon and nuclease free water to
50 μl. The PCR program was the same as the aforemen-
tioned with the exception of 8 cycles repeated for steps
2-4. Amplicons were visually checked on 2% agarose gels,
purified using SPRI select beads (Beckman Coulter) and
quantified through fluorometric Qubit dsDNA HS Assay
Kit (Thermo Scientific, Ireland). Equimolar amounts of
DNA per amplicon were then pooled and sequenced by
GATC Biotech, Germany on an Illumina MiSeq using a
2 × 250 bp paired end sequencing run.
Shotgun metagenomic sequencing
Genomic DNA was extracted as described above. The
DNA quality was checked on 1% agarose gel as well as a
Bioanalyser. Five μg of high molecular weight DNA were
sent to BGI TECH Solutions CO (Hong Kong) for se-
quencing on Illumina HiSeq (HiSeq 2500/4000) using
2 × 125 bp paired-end chemistry.
Bile and fatty acid measurements
Bile acids were extracted as previously described [30].
Briefly, 100 mg faeces was added to Dyna beads® (Roche)
with 300 μl of ice cold 50% methanol containing deuter-
ated internal standards of both CA and CDCA, then
subjected to five 30 s rounds of extraction in a Dynalyser
machine (Roche) at 6000 rpm. The mixture was vor-
texed and then centrifuged for 10 mins at 10,000 g and
the supernatant transferred to a fresh tube. Two ml of
ice cold acetonitrile (ACN) with formic acid was added
to each tube, vortexed and agitated at room temperature
for 1 h. Samples were centrifuged again to pellet the
debris and the supernatant was added to fresh tubes
containing 1 ml of ice cold 100% ACN. The samples
were vortexed and dried under vacuum at 4 °C. The
dried extracted acids were re-suspended in 150 ml of ice
cold 50% methanol.
Conjugated bile salts and free bile acids for standards
were purchased from Sigma Aldrich and Steraloids, Inc.
(Wicklow, Ireland and Newport, Rhode Island). HPLC-
grade methanol, acetonitrile, water, ammonium acetate,
ammonium formate, ammonium hydroxide, formic acid,
and acetic acid and water were obtained from Fisher Sci-
entific (Fair Lawn, NJ). Deuterated cholic acid (D-2452)
and deuterated chenodeoxycholic acid (D-2772) were pur-
chased from CDN Isotopes Inc. Standards were prepared
as 1 mg/ml stock solutions of individual sulphated bile
acids in water: methanol (1:1). They were subsequently
combined to a final volume of 1.0 ml in water to give a
stock concentration of 40 mg/ml. Subsequent dilutions
were made to which the same volume of deuterated stan-
dards was added. Fatty acids were treated similarly but
resuspended in 100% methanol. These standards were uti-
lized to create standard curves for each analyte examined
(Additional file 1: Tables S2 and S4).
Ultra Performance Liquid Chromatography Tandem Mass
Spectrometry (UPLC-MS)
UPLC-MS was performed as described [30] with minor
modifications. Briefly, 5 μL from each sample were
injected onto a C18 Acquity column (Waters Corp. Herts,
United Kingdom). Each sample was run in triplicate. Ex-
tracts were eluted using a 25-min gradient of 100% A to
100% B (A, water, 0.1% formic acid; B, acetonitrile, 0.1%
formic acid) at a flow rate of 500 μL/min and column
temperature of 40 °C. Samples were analyzed using an
Acquity system (Waters Ltd. Herts, United Kingdom)
coupled online to an LCT Premier mass spectrometer
(Waters MS Technologies, Ltd.) in negative electrospray
mode with a scan range of 50–1000 m/z. Bile acids, long
and medium chain fatty acids ionize strongly in negative
mode, producing a prominent [M-H] − ion. Capillary
voltage was 2.4 Kv, the sample cone was 35 V, the desolva-
tion temperature was 350 °C, the source temperature was
120 °C, and the desolvation gas flow was 900 L/h. Analysis
was performed using Waters software Targetlynx for exact
quantification against a standard curve and Markerlynx
for non-biased principle component analysis UPLC.
Bioinformatic and statistical analysis
16S amplicon sequences were processed as described else-
where [31]. Shotgun sequencing data was processed as fol-
lows: Sequencing reads were aligned to the human genome
(hg20) using bowtie2 [32] and filtered for quality using
trimmomatic [33]. Filtered reads were then analysed using
humann2 [34].
Statistical analysis was carried out using the program-
ming language R (Additional file 1: Table S5) [35]. Standard
visualizations were carried out using base R or ggplot2
[36]. Unweighted UniFrac distances were calculated in
QIIME [37] using data rarified to the lowest sequencing
depth per sample (4211 sequences) and were visualized
using function s.class [38]. Statistical significance was
established using permutational analysis of variance (PER-
MANOVA) using distance matrices and the function
adonis of the vegan package [39]. Statistical significance for
α-diversity measures was established using a two-tailed
Student’s t-test. Normal distribution of α-diversity values
was confirmed using a Kolmogorov-Smirnov test (all
p-values > 0.05). Differential abundance of microbial genera
between groups was assessed using DESeq2 [40] with an
FDR < 0.1. Other P-values were adjusted using the function
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p.adjust (stats package of base R) and the method of
Benjamini and Hochberg [41]. Significance was assumed
for adjusted P-values equal to or below 0.1, if not stated
otherwise. Statistical significance for bile acids and fatty
acids was established using a Wilcoxon rank sum test. For
determination of co-abundance groups, we first calculated
the pairwise correlation matrix of microbial genera present
in 37% of individuals using available python scripts for the
programme SparCC [42]. The heatplot was then generated
using the function heatplot with Ward linkage clustering,
Pearson correlation distance and no scaling. PCoAs (Prin-
cipal co-ordinates analysis) were determined using the
Spearman-rank distance of faecal bile acid levels or faecal
fatty acids, respectively.
Results
Clinical response to FMT
Ten patients underwent FMT in this study. Eigth were
female, 2 were male, with a mean age of 54 years, and
ages ranging from 22 to 90 years. The patients were
given a stool transplant via gastroscopy to the duodenum
as well as via colonoscopy to the distal ileum and right
colon, as there was uncertainity with regard to the most
effective route of delivery. The choice of bi-directional
esophago-gastro-duodenoscopy and full colonoscopy
was empirical to maximise the chance of success. Nine
patients underwent antibiotic treatment prior to C. dif-
ficile associated diarrhoea, the remaining patient having
pre-existing ulcerative colitis (Table 1). In terms of
treatment regimens, 9 had undergone 3 or more anti-
biotic courses and 6 had undergone 4 or more. These
courses included various regimens of the standard
treatments, metronidazole, vancomycin and fidaxomi-
cin. All patients had failed multiple courses of therapy
for C. difficile with metronidazole, vancomycin and fidax-
omicin prior to FMT. There was no antibiotic treatment
given for 48 h before transplant. Nine out of ten patients
improved clinically and remained C. difficile toxin nega-
tive for between 6 months to 2 years after a single FMT
(Table 1). The patient who relapsed after FMT with ma-
terial from a donor they selected had previously required
colonic resection with ileorectal anastomosis for toxic
megacolon due to C. difficile. This patient was found to
have very high levels of glyco conjugated bile acid (~ 7500
μg/g) and taurine (~ 2500 μg/g) pre-FMT compared to
most of the good responders of the transplant (who had
very little or none of both glyco conjugated bile acid and
taurine) (Additional file 1: Figure S4). Post FMT, the levels
of both glyco-cojugated bile acids and taurine were
reduced to < 500 μg/g for patient 1 (the initially failed
FMT patient) (Additional file 1: Figure S4). However, this
patient also improved clinically after a second FMT with a
different donor.
FMT moves the microbiota of recipients towards that of
the donor and improves bacterial diversity
Microbiota profiles for 27 samples were obtained using
16S rRNA gene sequencing. Of these, 10 samples were
obtained pre FMT (called “recipient” and designated “R”
in Fig. 1), 7 were acquired between 1 and 4 months post
FMT (“recipient-follow-up”/“RF”) and 10 samples were
obtained from donors (“donor”/“D”). Only 7 follow-up
samples were obtained as collection of the follow-up
samples were time dependent and not all the patients
could provide one. All patients who provided follow-up
samples were in clinical remission when they provided
the sample except for the first patient who failed the ini-
tial FMT and required a second with a unit from a dif-
ferent donor. Of the 10 donor samples, one was from
the stool bank OpenBiome. The minimal sequencing
depth per sample was 4211 reads. The overall microbiota
of the patients with C. difficile infection was different from
the donor microbiota (p < 0.001, PERMANOVA; Fig. 1
and Additional file 1: Figure S5). However, after FMT the
composition of the microbiota was more similar to that of
the donor (Fig. 1a and Additional file 1: Figure S5). Princi-
pal coordinates analysis of the unweighted UniFrac
distances between the samples revealed that follow-up
samples were more closely related to the donor than to
the recipient (Fig. 1a and Additional file 1: Figure S5). This
showed that FMT resulted in partial recovery of gut mi-
crobial community structure and the establishment of a
more donor-like microbiota (Fig. 1a and Additional file 1:
Figure S5). These compositional differences were also
reflected in the bacterial diversity which we measured
using several widely recognized measures of α-diversity:
Chao1 index, Phylogenetic Diversity (Fig. 1b, c), and
Simpson index, and observed species. For all indices,
the alpha diversity was statistically significantly lower
prior to FMT compared to donor samples (P-values from
2×10− 4 to 0.01, Student’s t-test) but recovered to levels
observed in the donor samples post FMT (Fig. 1b).
However, even though the diversity indices improved
following FMT, the levels observed were still lower
after the FMT-procedure compared to donor levels
(73 - 88% of the donor-samples’ diversity index values,
range of P-values from 0.05 to 0.19, depending on the
index used) (Fig. 1b, c).
Community structure and compositional changes in the
microbiota at phylum and genus levels after FMT
Noteworthy differences at both bacterial phylum and genus
levels were observed in recipient, follow-up and donor
samples (Additional file 1: Figure S1 & Additional file 2:
Table S6). The abundances of several individual genera or
species clusters, including Proteus, Sutterella, Fusobacter-
ium, Clostridium_XVIII, Veilonella, Escherichia/Shigella,
Klebsiella, Acidaminococcus and Streptococcus (P < 1e-03,
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Wald test) were significantly higher in patients with C. dif-
ficile infection (Additional file 1: Figure S1) compared to
donors. The levels of most of the aforementioned bacteria
approached donor levels post-FMT indicating successful
colonization and established communities from the donor
microbiota. Only Faecalibacterium was found to be lower
in the patients with C. difficile infection compared to the
donors (P < 0.1).
Further analysis of the microbiota was performed by
determining Co-Abundance Groups (CAGs), i.e. clusters
of co-occurring bacteria, an analytical approach employed
productively in our previous microbiota analyses [31, 43, 44].
Four CAGs were identified based on the correlations
between genera and determined by SparCC [42] (Fig. 2).
Most bacterial genera with elevated abundance in recipients
were found in one CAG (orange CAG 2 in Fig. 2, Add-
itional file 1: Figures S2 & S3), reflecting similarities in
terms of microbiota composition among patients. Contrast-
ingly, bacteria with relatively high abundance in donors
were grouped in CAG 1 and CAG 3 (turquoise and purple
CAGs in Fig. 2, Additional file 1: Figures S2A & S3). The
bacteria in these two CAGs are indicative of the presence
of Bacteroides and Ruminococcus-like enterotypes [45],
respectively, in the donor samples. A Prevotella-like entero-
type was not detected in this cohort. We have noted that
some RF samples still clustered with R samples (Fig. 1) indi-
cating that microbiota community transplanted from the
donor was not established properly in the recipient.
Fig. 1 FMT restores the microbiota to a more donor-like profile. a: Overall the microbiota composition is more similar to the donor microbiota
after FMT compared to before transplant. Shown is the PCoA (unweighted UniFrac distance) of the microbiota associated with CDI (“R”, n = 10),
post-FMT (“RF”, n = 7) as well as FMT-donors (“D”, n = 10). The tenth sample can be found in the bottom-right part of the PCoA overlaping one of
the RF samples. The microbiota prior to FMT is statistically significantly different, compared to the microbiota of donors (P < .001, F-statistic = 4.96,
PERMANOVA), but assumes a more donor-like profile after FMT (P > .1, F-statistic = 1.22 for “RF” vs “D”). b and c: FMT leads to partial recovery of
bacterial α-diversity. Shown, are box-and-whisker plots for the Chao1 index (b) and the phylogenetic diversity (PD whole tree) (c). Similar results
were obtained for three other measures of bacterial α-diversity (Shannon- and Simpson-index, observed species). ‘***’ P < .001; ‘**’ P < .01; ‘*’
P < .05; ‘.’ P < .1
Brown et al. BMC Gastroenterology  (2018) 18:131 Page 6 of 15
Similarly, for some of the samples the bacterial α-diversity
did not improve upon FMT treatment (Fig. 1b and c). We
hypothesized that this could be explained by the microbiota
profiles of either the donor or the recipient. To test this, we
determined the change in terms of bacterial α-diversity in-
duced by the FMT treatment and then correlated this
change with the abundance of the four detected CAGs in
the donor samples. The abundance of CAG 2 and CAG 3
Fig. 2 Hierarchical Ward-linkage clustering based on the correlation coefficients determined by SparCC. Co-abundance groups were defined on
the basis of the clusters in the vertical tree. Colour coding of side bars: Co-abundance groups are coloured according to the legend at the
bottom-right. Fold-change and statistical significance are coloured according to the legend at the bottom-left. Colour coding of the side bars
according to the legends below. The composition of each Co-abundance Group is shown in Additional file 1: Figure S2
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in the donor samples was negatively (Spearman’s ρ = − 0.79,
p = − 0.05) and positively (Spearman’s ρ = 0.82, P = 0.03)
correlated, respectively, with the increase in bacterial
α-diversity upon FMT treatment (Fig. 2 & Additional file 1:
Figure S2). Additionally, the abundance of CAG 2 in donor
samples was negatively associated with the abundance of
CAG 3 in RF samples (Spearman’s ρ = − 0.82, P = 0.03)
(Fig. 2 & Additional file 1: Figure S2). While this part of the
analysis was not corrected for multiple testing due to the
small sample size under consideration, this qualified pre-
liminary observation may add to the rationale for choosing
optimal donor samples for FMT.
Faecal bile acid levels are significantly different in donors
and recipients and are more donor-like in FMT recipients
Faecal bile acids were quantified in samples from 5
donors, 7 patients and 6 recipients post-FMT. Analysis
of the patients’ faecal bile acid levels revealed more
donor-like profiles after FMT compared to before trans-
plant (Fig. 3). The FMT effect in the majority of cases
was to substantially increase and to restore the diversity
of faecal bile acid levels (mean of 6651 μg/g in the re-
cipient samples, 15,243 μg/g in the follow-up samples)
(Fig. 3b). Here, similar to other studies, patients with C.
difficile infection showed decreased levels of secondary
bile acid, DCA, LCA and ursodeoxycholic acid. The
levels of primary free bile acid were significantly elevated
in individuals with C. difficile infection compared to do-
nors (P < .05; Fig. 3b). This may account for the lower
levels of overall bile acid in the faeces because CDCA is
a potent ligand of farnesoid X receptor which signals
through fibroblast growth factor 19 in the liver to lower
bile acid synthesis [46–48]. Generally, tauro-conjugated bile
acid levels were low (Fig. 3b) indicating that microbial bile
acid deconjugation was unaffected in these individuals and,
as with previously reported studies, 7α-dehydroxylation
and epimerization by other microbial enzymes (from
members of the Firmicutes containing the bai operon
components) were depleted. Since the only experimentally
confirmed 7α-dehydroxylation activity is found among
Clostridium species, the use of Clostridium targeting anti-
biotics may be responsible for the loss of this activity. In
combination with this, the use of elemental nutrition may
also reduce C. difficile colonization resistance in these pa-
tients. C. difficile itself is equipped to deconjugate bile
salts but does not have 7α-dehydroxylation ability. The
levels of these secondary bile acid were restored post FMT
and primary bile acid CDCA and CA decreased (Fig. 3b).
Overall, glyco-conjugated bile acids levels were signifi-
cantly higher in patients pre-FMT compared to donors
Fig. 3 FMT restores faecal bile acids to more donor-like levels. a: Overall, the bile acid levels are more similar to those seen in the donor after
FMT compared to before transplant. Shown is the PCoA (Spearman rank distance) of the bile acid levels associated with CDI (“R”, n = 7), post-FMT
(“RF”, n = 6) as well as FMT-donors (“D”, n = 5). The bile acid profile before FMT is statistically significantly different compared to the microbiota of
the donors (P < .01, PERMANOVA) but assumes a more donor-like profile after FMT (P > .1 for “RF” vs “D”). b: Many bile acids are restored to donor
levels after FMT. Shown are boxplots for bile acids with differential abundance (P < .1) in patients with CDI (“R”) compared to the donors (“D”).
Most of these faecal bile acids were not differentially abundant after the FMT procedure (“RF”) compared to the donors, indicated by asterix. D:
donor, R: recipient, RF: recipient post-FMT, CA: DCA:, GDCA:, GlyCon: merged glyco-conjugated bile acids, HCA:, LCA:, P: merged primary bile acids,
ST: merged secondary and tertiary bile acids, UDCA:, LCA:, DCA:, CA:, HCA:,GDCA
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(Fig. 3b). Taken together we can confirm that patients
with C. difficile infection show a decreased secondary bile
acid profile while upstream precursor molecules are ele-
vated in these patients (Fig. 3b).
Interestingly, in assessing the bile acid signature in
donor samples it is clear that different donors alter bile
acid and salt moieties to different extents. Fresh material
prepared under anaerobic condition appear capable of ele-
vating secondary bile acid to a greater degree than frozen
commercially available donor material (Additional file 1:
Table S3). Furthermore, the level of conjugated bile acid
in frozen material was 7-12 times lower than that of the
fresh donor samples.
Microbiota profiles strongly correlate with faecal bile acids
Both microbiota and faecal bile acid data were available
for 4 donors, 6 recipients pre-FMT and 4 recipients
post-FMT. Co-inertia analysis of the microbiota and bile
acid data based on the PCoAs shown in Figs. 1 and 3 was
performed, and revealed a consistent relationship between
the two datasets (Fig. 4a). Moreover, despite the small
number of samples, both the overall profile of faecal bile
acids as well as individual bile acids were statistically
significantly correlated with the relative abundance of sev-
eral bacterial genera (Fig. 4b-d).
We used network plots to examine the relationship be-
tween bacterial genera and bile acids, since gut bacteria
are known to play a key role in hydrolysing primary to
secondary bile acids, thereby conferring resistance to C.
difficile infection [49]. The network plots (Fig. 4c and d)
represent the relationship between bacterial genera and
bile acid levels. Particularly interesting is that bacterial gen-
era classified as Anaerotruncus, Coprococcus, Defluviitalea,
Faecalibacterium, Gemmiger, Odoribacter, Oscillibacter,
Ruminococcaceae, Ruminococcus, and Sporobacter, that
were statistically significantly negatively associated with
primary bile acid levels, were also statistically significantly
positively related with secondary bile acid DCA and LCA
levels (Fig. 4c and d). These genera are also known to
differentially confer resistance to growth and germination
of C. difficile [50–57]. Likewise, bacterial genera such as
Enterococcus and Lactobacillus were found to be positively
associated with primary bile acid levels and negatively
related with secondary bile acid levels (Fig. 4c and d).
Faecal fatty acid levels are significantly different in donors
and recipients
Inflammatory mediators are the link between innate and
adaptive immunity. Inappropriate damage to host tissue
through uncontrolled inflammation via pathogen toxins
or endotoxins is proposed to release cellular fatty acids in
CD infection [58]. Fatty acids, particularly PUFA metabo-
lised to eicosanoids, are a key factor to mediate and regulate
the inflammation response [59]. ω-3 PUFA and arachidonic
acid is a key precursor of inflammatory cells and its levels
dictate the duration and intensity of the response. On the
other hand, ω-6 PUFA Docosahexaenoic acid (DHA) and
Eicosapentaenoic acid (EPA) moderate the effect of
arachidonic acid and its downstream products through
anti-inflammatory resolvins, docosatrienes, neuroprotec-
tins for DHA and E series resolvins via EPA. Since there is
a proposed link between PUFAs and gut health [60, 61],
we decided to profile a number of FAs. Individuals with C.
difficile infection showed differences in the levels of 14
FAs examined relative to healthy donors, and PCoA ana-
lysis did not demonstrate overall conversion of FA profiles
to the donor type in recipients (p > .1, PERMANOVA;
Fig. 5a). Although reduced levels of short chain fatty acids,
butyrate, propionate and acetate, have been previously re-
ported by Seekatz et al., [62], we found elevated levels of
fatty acids in patient groups relative to donors. This in-
cluded SCFA, pyruvic acid and lactic acid, saturated fatty
acids palmitic acid, and myristic acid – also an ω-6 FA,
monounsaturated FAs, oleic acid and palmitoleic acid, ω-3
PUFAs α-linolenic acid and γ-linolenic acid (ALA+GLA)
and EHA and DHA as well as, ω-6 Linoleic acid and
arachidonic acid (Fig. 5a). There was some indication of a
normalisation of individual inflammatory FA levels in recip-
ients. SCFA, ω-3 & ω-6 PUFAs were altered in the direction
of the donor following FMT (Fig. 6b). The relative ratios of
detected anti-inflammatory ω-3 to pro-inflammatory ω-6
PUFAs in healthy donors was 1:1.3, for the C. difficile pa-
tient group this ratio was 1:1.8 and this ratio was altered
post FMT to 1: 1.4. Taken together these data indicate that
patients with C. difficile infection show higher levels of FA
that may be indicative of inflammatory cell recruitment as
well as liberation of cell membrane arachidonic acid or of
increased dietary fermentation by microbes. Although FA
levels remain high the relative dilution effect of ω-3 PUFA
is evident post FMT and may be taken as an indicator or
biomarker of reduced inflammation post FMT.
Archaeal abundance revealed by metagenomic sequencing
Detection of archaeal taxa by bacterial 16S rRNA gene
primers is unreliable [63]. We performed metagenomic
shotgun sequencing for 4 follow-up samples post FMT
and 4 donor samples (1.97 × 107 mean read count after
quality filtering, 2.73 × 105 standard deviation). Similar sam-
ple stratification as for the microbiota profiles was obtained
using functional profiles (Additional file 1: Figure S6) and
we found that genes associated with archaeal metabol-
ism were enriched in the follow-up samples, post FMT
(Additional file 1: Figure S6). More detailed analysis
showed that the contributing microorganisms were either
Methanobrevibacter smithii or Methanosphaera stadtma-
nae (Additional file 3: Table S7). Curiously, when genes for
archaeal metabolism were detected in a follow-up sample,
archaea were of lower abundance in the respective donor
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Fig. 4 Bile acid and microbiota profiles are strongly correlated. a Co-inertia analysis of the microbiota and bile-acid based PCoAs from
Additional file 1: Figures S1 and S4. Circles: location of sample is based on microbiota data; end of lines: location of sample is based on bile acid
data; the length of each line is proportional to the difference between the bile acid and microbiota data; RV: measure of similarity on a scale
from 0 to 1, the closer to 1, the greater the similarity between the two datasets. b Clusters of bacteria are strongly associated with bile acid levels,
particularly primary (red column bar) and secondary and tertiary bile acids (green column bar). Shown is the heatmap of the Spearman
correlations between the level of bile acids and bacterial genus log-ratio abundance (dark blue: positive correlation, white: negative correlation;
scale in legend top-left). Column annotation as in legend top-right; row annotation (from left to right): 1 Fold change of bacterial abundance
between patients pre-FMT and the donors (colours as in Fig. 2). 2-6 Spearman correlation coefficient between bacterial genera and combined
bile acids. Dark green: positive correlation; white: negative correlation. From left to right: T, ST, P, GlyCon and TauCon. 7 CAG-membership for
each bacterial genus (colours as in Fig. 2). c and d Network plots of bacterial genera. The sign of the Spearman correlation coefficient with
primary faecal bile acids (c) and secondary and tertiary bile acids (d) is indicated for each genus. Upward-facing triangle: statistically significant
positive correlation. Circle: not statistically significantly correlated. Downward facing triangle: statistically significant negative correlation. Colours of
circles indicate CAG-membership of bacterial genera; colour code as in Fig. 2. The size of the circle or triangle is proportional to the mean relative
abundance of the represented genus from all samples
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sample or not found at all (Additional file 1: Figure S6).
Moreover, for one paired set, archaeal metabolism genes
were found in the donor sample but not in the follow-up
sample (Additional file 1: Figure S6).
Discussion
In this study, we established faecal microbiota changes
that correlated with bile and faecal fatty acid profiles of
10 patients with relapsing C. difficile infection after they
successfully received therapeutic FMT. Patients with C. dif-
ficile overgrowth had a distinct low diversity microbiome
prior to FMT, but acquired a more diverse microbiota
resembling the donors after transplantation. Interestingly,
while mean α-diversity was significantly higher in FMT
recipients, values were not completely restored to donor
levels, and the degree of restoration correlated with the
representation of certain co-abundance groups in the
donor sample. This may allow FMT donor stratification or
selection for efficacy in future. Additionally, in support of
this we describe the case of patient FMT01 who experi-
enced a failed FMT with their own selected donor, and
a microbiota comprising of CAG 2 (consisting mainly
the phylum Proteobacteria), post-transplant, compared
to a good responder such as FMT07, where the micro-
biota was more diverse, consisting of CAGs 1, 2 and 3
(Additional file 1: Figures S2 & S3).
Age is known to be one of the predisposing factors for
the development of C. difficile infection, because older
people have a microbiota that is apparently permissive.
Studies carried out on elderly cohorts have reported an
increase in Bacteroidetes and Proteobacteria and a decrease
in some Firmicutes as well as Bifidobacteria [43]. Previous
studies have reported that the presence in FMT patients of
the following taxa, Bacteroides spp., Alistipes, Rumi-
nococcaceae, Clostridium cluster IV, Clostridium clus-
ter XIVa, Lachnospiraceae, Peptostreptococcaceae and
Verrucomicrobiaceae are protective against C. difficile
colonization, whereas Lactobacillus spp., Streptococca-
ceae, Enterobacteriaceae, Veillonella, Enterococcus
spp., Salmonella spp. and Sutterella spp., were associ-
ated with susceptibility [26, 53, 64–68]. We observed
increased abundances of Clostridia and Bacilli as well
as members of the phylum Bacteroidetes in samples
from healthy donors (Additional file 1: Figure S1. CAGs
1 & 3) compared to patients with C. difficile infection [69].
The largest groups within these two phyla were Clostridia
and Bacteroidia. Depletion of key bacterial species within
these two phyla may reduce protection against C. difficile
associated diarrhoea.
Higher faecal levels of primary bile acids were measured
in patients with recurrent C. difficile infection prior to
FMT in comparison to the donors (Fig. 3, Additional file 1:
Figure S4) and these levels decreased following FMT. This
is consistent with findings of a previous study [64]. After
FMT, we noted that the levels of secondary bile acids were
restored towards levels seen in the donor. We also
observed that the levels of secondary bile acids detected
in the faecal sample of a good responder to FMT
post-transplant were more than twice the levels found in
the patient with the failed procedure (~ 13,000 μg/g for
the former and ~ 5000 μg/g for the latter) Additional file 1:
Figure S4. Secondary bile acids are exclusively produced
by bacterial metabolism in the large intestine. Primary bile
acids such as CA and taurocholate promote germination
of C. difficile spores, whereas secondary bile acids LCA
generally inhibit germination and growth [70–72]. Alter-
ation in the normal microbiota of the gut by antibiotic
treatment, in particular the elimination of species capable
of 7α-dehydroxylation of primary bile salts, causes an
increase in the concentration of CA primary bile salts and
a decrease in the concentration of secondary bile salts
(DCA) [73]. This in turn affects C. difficile germination
Fig. 5 FMT does not restore faecal fatty acids to donor levels. a Donor-associated faecal fatty acids are distinct from recipients and follow-ups
whereas faecal fatty acids do not change significantly after FMT. Shown is the principal coordinate analysis based on the faecal fatty acid levels
(Spearman rank distance). b Boxplots showing levels of 14 faecal fatty acids. Statistical significance was calculated using a Wilcoxon rank sum test.
P-values were adjusted for multiple testing using the method from Benjamini and Hochberg. Significance (P < .1) is indicated by circles. D: Donor
(n = 3), R: Recipients (n = 7), RF: Follow-up (n = 4)
Brown et al. BMC Gastroenterology  (2018) 18:131 Page 11 of 15
and growth. Theriot et al. also reported that changes in
the microbial community structure of mice treated with
antibiotics correlated with shifts in secondary bile acids
[51]. Elevated free and glyco-conjugates of CDCA have
the effect of inhibiting germination of CD spores, an effect
that can also be blocked by the secondary bile acid
Fig. 6 Faecal fatty acid levels are correlated with the abundance of several bacterial genera. Shown is the heat map of the Spearman correlations
between faecal fatty acids (columns) and bacterial genus log-ratio abundance (rows). Column annotation: fold R vs D: fold-change of faecal fatty
acids between recipients (“R”) and donors (“D”); red: > 1; green < 1. CAG1-4: Spearman correlation of fatty acid levels with log-ratio abundance of
bacterial CAGs (Fig. 2). White: negative correlation, dark green: positive correlation. Row annotation: Left: Fold change of bacterial abundance between
individuals pre-FMT (R) and donors (D). Right: CAG-membership for each bacterial genus. Colours for both as in Fig. 2
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ursodeoxycholic acid, while vegetative growth is enhanced
by deoxycholic acid [70, 74, 75]. Interestingly CA and
CDCA can alter Na+/K+ channel activation to prevent re-
moval of water in the gastrointestinal tract and therefore
induce bile acid diarrhoea, contributing to the disease [76].
The microbial populations present in the lower GI
tract dictate the bile acid signatures that can either pro-
mote or prevent C. difficile outgrowth and colonization,
effects that are resolved through FMT via both bile acid
alteration to prevent outgrowth, and by colonization re-
sistance restoration through the microbiota. Resolution
or recovery from C. difficile infection may also be associ-
ated with the successful transfer of 7α-dehydroxylation
bile acid inducible C. difficile (baiCD) genes. Solbach et al.
reported reduced prevalence of the baiCD gene cluster in
C. difficile patients and found successful FMT therapy in 1
out of 2 patients with recurrent C. difficile infection was
associated with acquisition of baiCD genes [77].
We identified some normalisation of fatty acid profiles
after FMT which correlated positively with Firmicutes
abundance (the main contributor to taxa comprizing
CAGs 1 and 3 in Fig. 6). This normalization comprised
of elevation in the levels of some monounsaturated fatty
acids and reduction in long chain polyunsaturated fatty
acid levels. It may be that some of these long chain fatty
acids are being metabolised by Firmicutes in syntrophy
with gut microbes to generate energy. The mechanistic
role of this in symptomatic recovery remains uncertain.
We also acknowledge that the numbers in our study are
small and the effect of fatty acid is very modest.
The finding of genes for archaeal metabolism in a
follow-up sample, and their lower abundance or absence
in the respective donor sample, as well as the presence
of genes in the donor but not in the follow up sample, is
intriguing (Additional file 3: Table S7). Methanogens are
sensitive to drugs commonly used to treat C. difficile
such as metronidazole [78] and it is likely they are rou-
tinely eliminated in C. difficile patients as a by-product
of standard therapy prior to transplant. They are not
present in all people and are also adversely affected by
statins. Most bacteria are not affected by statins which
can however specifically interfere with cell membrane
synthesis in archaea [79]. Donors and recipients were not
screened for non-antibacterial medication. One explan-
ation for the lack of methanogen congruence between
donor and recipients could be that both groups may con-
tain individuals with low level methanogen colonization
due to suppression by statin therapy.
In summary, FMT restores the microbiota of patients
with C. difficile infection to a state closer to that of the
donor in respect of alpha diversity and co-abundance
group microbiota structure, while it effectively treats the
illness. A major metabolic signature of this transform-
ation is a reduction in levels of primary bile acids and an
increase in levels of secondary bile acids, both of which
are likely to impact adversely on C. difficile growth and
germination. We have confirmed previous reports that
specific bile acid profiles are associated with C. difficile
associated diarrhoea. Related to this, we found that the
combination of key genera such as Ruminococcus and
Bacteroides appears to be inherently linked to the me-
tabolism of secondary bile acids and would therefore be
protective against C. difficile colonisation. A lesser effect
was noted for fatty acids. Lastly, FMT had a limited effect
on archaeal ecology in the recipient samples although we
could not verify this from the 16S data. While FMT as a
treatment of C. difficile infection is usually successful and
was so in the current study, a short-term effect of archaea
is not apparent in this context, but long-term effects may
be possible.
Conclusions
Patients whose C. difficile infection was successfully treated
by faecal transplantation experienced a microbiota shift
towards that of the donor with a metabolic signature
reflecting normalisation of bile acid metabolism that may
be the mechanism of transplantation efficacy. An effect on
the ratios of inflammatory and non-inflammatory FAs was
also noted. Donor microbiota taxa associated with res-
toration of bile acid metabolism and microbial diversity
were variably present in donors, suggesting rational donor
selection may be possible.
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